logo
Major reports about how climate change affects the US are removed from websites

Major reports about how climate change affects the US are removed from websites

CTV News3 days ago
WASHINGTON — Legally mandated U.S. national climate assessments seem to have disappeared from the federal websites built to display them, making it harder for state and local governments and the public to learn what to expect in their backyards from a warming world.
Scientists said the peer-reviewed authoritative reports save money and lives. Websites for the national assessments and the U.S. Global Change Research Program were down Monday and Tuesday with no links, notes or referrals elsewhere. The White House, which was responsible for the assessments, said the information will be housed within NASA to comply with the law, but gave no further details.
Searches for the assessments on NASA websites did not turn them up. NASA did not respond to requests for information. The U.S. National Oceanic and Atmospheric Administration, which coordinated the information in the assessments, did not respond to repeated inquiries.
'It's critical for decision makers across the country to know what the science in the National Climate Assessment is. That is the most reliable and well-reviewed source of information about climate that exists for the United States,' said University of Arizona climate scientist Kathy Jacobs, who coordinated the 2014 version of the report.
'It's a sad day for the United States if it is true that the National Climate Assessment is no longer available,' Jacobs said. 'This is evidence of serious tampering with the facts and with people's access to information, and it actually may increase the risk of people being harmed by climate-related impacts.'
Harvard climate scientist John Holdren, who was President Obama's science advisor and whose office directed the assessments, said after the 2014 edition he visited governors, mayors and other local officials who told him how useful the 841-page report was. It helped them decide whether to raise roads, build seawalls and even move hospital generators from basements to roofs, he said.
'This is a government resource paid for by the taxpayer to provide the information that really is the primary source of information for any city, state or federal agency who's trying to prepare for the impacts of a changing climate,' said Texas Tech climate scientist Katharine Hayhoe, who has been a volunteer author for several editions of the report.
Copies of past reports are still squirreled away in NOAA's library. NASA's open science data repository includes dead links to the assessment site.
The most recent report, issued in 2023, included an interactive atlas that zoomed down to the county level. It found that climate change is affecting people's security, health and livelihoods in every corner of the country in different ways, with minority and Native American communities often disproportionately at risk.
The 1990 Global Change Research Act requires a national climate assessment every four years and directs the president to establish an interagency United States Global Change Research Program. In the spring, the Trump administration told the volunteer authors of the next climate assessment that their services weren't needed and ended the contract with the private firm that helps coordinate the website and report.
Additionally, NOAA's main climate.gov website was recently forwarded to a different NOAA website. Social media and blogs at NOAA and NASA about climate impacts for the general public were cut or eliminated.
'It's part of a horrifying big picture,' Holdren said. 'It's just an appalling whole demolition of science infrastructure.'
The national assessments are more useful than international climate reports put out by the United Nations every seven or so years because they are more localized and more detailed, Hayhoe and Jacobs said.
The national reports are not only peer reviewed by other scientists, but examined for accuracy by the National Academy of Sciences, federal agencies, the staff and the public.
Hiding the reports would be censoring science, Jacobs said.
And it's dangerous for the country, Hayhoe said, comparing it to steering a car on a curving road by only looking through the rearview mirror: 'And now, more than ever, we need to be looking ahead to do everything it takes to make it around that curve safely. It's like our windshield's being painted over.'
Associated Press writer Will Weissert contributed to this report.
The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.
Seth Borenstein, The Associated Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

Globe and Mail

time2 hours ago

  • Globe and Mail

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

Key Points Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all downside hedges. Despite trading near 52-week lows due to biotech industry headwinds, Viking's oral GLP-1 drug shows unprecedented tolerability that could revolutionize obesity treatment. Upcoming phase 2 oral data expected in October or November 2025 represents a rare binary event where the market significantly undervalues the upside potential. Most investors have written off biotech stocks as a graveyard of broken dreams. While artificial intelligence (AI) captures Wall Street's imagination, the biotech industry -- once the crown jewel of innovation -- has been left for dead. But beneath the wreckage, Wall Street's sharpest funds are quietly positioning for what could be the most significant metabolic breakthrough in a generation. A differentiated player in the GLP-1 gold rush Viking Therapeutics (NASDAQ: VKTX) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company reported stellar phase 2 results in February 2024, showing 14.7% weight loss at 13 weeks with the injectable formulation. But here's what makes Viking different: Its drug demonstrated unprecedented tolerability with a 13% discontinuation rate that was no higher than placebo -- a stark contrast to competing GLP-1 drugs. In obesity treatment, tolerability isn't a luxury -- it's key to real-world adoption. Viking's breakthrough with VK2735 isn't just efficacy; it's safety. The drug's 13% discontinuation rate matched placebo -- unlike Wegovy and Zepbound, which see discontinuation rates typically five to 10 percentage points higher than their placebo groups. Tolerability indistinguishable from placebo could expand the entire obesity market -- not just capture share. The obesity drug market is projected to reach $200 billion by 2030, yet current treatments face significant limitations. Novo Nordisk 's Wegovy and Eli Lilly 's Zepbound require weekly injections and cause severe gastrointestinal side effects in many patients. Viking's oral formulation, currently in phase 2 trials with data expected in the October-to-November time frame, could be the first pill to roughly match injectable efficacy without the tolerability issues. Here's what Wall Street might be missing: Viking's superior tolerability profile doesn't just mean competing for market share -- it could lift the roof on the entire obesity category. With no greater discontinuation than placebo, VK2735 could dramatically expand the addressable market by reaching patients who currently avoid or quit treatment due to side effects. An effective, well-tolerated oral option could double or triple the number of patients seeking treatment. The numbers tell a compelling story: Viking showed a near-perfect dose-response relationship, with tolerability no different than placebo -- something no other GLP-1 developer has achieved. Every major pharma has tried and failed to create an effective oral GLP-1, with Pfizer discontinuing its program due to safety issues and an exceptionally high discontinuation rate (> 50%). Viking appears to have cracked the code based on the early data, and Wall Street seems to know it (more on that later). Why is the stock trading near 52-week lows? Viking's stock has plummeted 64% from its 52-week high of $81.73 to around $27 as of July 2. This devastation reflects broader structural damage in the biotech space rather than company-specific issues. Since interest rates have flipped higher, biotech as a whole has been crushed, leaving a bad taste in investors' mouths. The 2022 biotech collapse has created a vicious cycle. Great opportunities are no longer getting flagged for investors, as AI stocks dominate headlines and capture imaginations. Meanwhile, GLP-1 drugs have shown a mixed bag in clinical trials lately, suggesting to some that a top in efficacy and safety is near. But I believe that's shortsighted thinking. VK2735 has shown a differentiated clinical profile, with tolerability nearly indistinguishable from placebo in early studies -- something no other GLP-1 has achieved. While it's far too early to declare victory, the data suggests Viking may have solved one of the key challenges that has plagued obesity drugs. This widespread biotech pessimism has created the kind of mispricing sophisticated funds live for: quality assets trading at distressed valuations. It's the very definition of an asymmetric opportunity. The institutional positioning tells a different story While retail investors panic, institutional behavior reveals extreme confidence. Per the latest 13F filings, Balyasny Asset Management holds $71 million in bullish positions, up 542% from the previous quarter. Citadel owns $32 million, Susquehanna has $36 million, and Jane Street holds $17.5 million. Combined, these sophisticated quantitative funds have accumulated over $150 million in bullish positions. More telling is what Goldman Sachs just did: It eliminated 100% of its put positions while increasing calls by 350%. When one of Wall Street's premier trading desks removes all downside protection, it's signaling extreme confidence in the outcome. These institutions aren't speculating randomly -- they're arbitraging what they see as a massive market inefficiency. Their models likely show the same disconnect: a drug with tolerability on par with placebo, and a validated mechanism trading as if it has a 96.5% chance of complete failure. For quant funds that live and die by probabilities, this represents a rare mispricing opportunity. The divergence between institutional longs and retail shorts has reached an extreme. Short interest just increased to 30% of float as of June 13, up from 26% the prior month -- even as the smart money accumulates massive call positions. For context, 30% short interest is extraordinarily high for a clinical-stage biotech, putting Viking in the 99th percentile of U.S. equities for bearish bets. This sets the stage for a classic capitulation moment, where good news could ignite both fundamental revaluation and a violent short squeeze. A manufacturing partner validates the opportunity Manufacturing is the Achilles' heel of most small-cap biotechs. Viking solved this early. In March 2025, the company inked a $150 million manufacturing deal with CordenPharma -- one of the world's premier peptide contract development and manufacturing organizations (CDMOs) -- giving Viking turnkey capacity for 100 million autoinjectors and 1 billion tablets annually, without dilution or costly infrastructure builds. This agreement removes a major overhang that has plagued other clinical-stage biotechs, as well as serves as a clear green flag that the broader market has curiously decided to ignore. After all, such an agreement would not have been signed without deep due diligence and extreme confidence in VK2735's clinical profile. Why? There is a tsunami of demand for GLP-1 manufacturing capacity right now. The asymmetric setup ahead of oral data The phase 2 oral data release expected in the fourth quarter of 2025 represents a rare asymmetric opportunity. Based on the dose-response curves from the four-week data showing 6.8% weight loss, the oral formulation could potentially approach injectable-like efficacy. The full 13-week phase 2 data will reveal how close the oral formulation can get to the 14.7% weight loss seen with the injectable. At today's $3 billion market cap, Viking trades at a fraction of the value created by successful GLP-1 drugs. Eli Lilly has added over $300 billion in market value since Mounjaro's 2022 launch, while Novo Nordisk saw its valuation surge from under $200 billion to over $600 billion at its peak as Ozempic and Wegovy transformed the obesity market. Even with recent pullbacks, both companies have captured hundreds of billions in incremental value from their GLP-1 franchises alone. The market's high bar for new entrants was evident when Amgen 's MariTide showed 20% weight loss but disappointed with 11% discontinuation rates in its phase 2 trial. When the data was released in November 2024, shares fell nearly 5% that day despite the solid efficacy. Yet Viking's parity with placebo appears to clear that bar with room to spare. If Viking's oral drug approaches the injectable's efficacy, the stock could see immediate revaluation to $200 to $300 per share, with longer-term potential exceeding $500. At current levels, the market is implying just a 3.5% probability of success for VK2735. That's absurd when you consider that metabolic drugs with positive phase 2 data typically have 45% to 50% success rates through approval. With VK2735's validated mechanism and placebo-like tolerability, a reasonable probability may range from 45% to 70% -- significantly above the market's implied odds. Even using just a 25% success rate -- below the industry average -- suggests the stock should trade above $100 right now. At $27, the market is pricing Viking as a lottery ticket. The data says it's closer to loaded dice. The risk-reward setup has convinced me to take a leveraged position through deep out-of-the-money call options -- admittedly a speculative position that could expire worthless. But with Viking having about $7.50 per share in cash, even equity investors have defined downside risk in a worst-case scenario. Add in 30% short interest providing squeeze fuel and institutional positioning at extreme levels, and the asymmetric opportunity becomes clear. Time to look past the biotech wreckage Key risks include potential safety issues emerging in larger trials, manufacturing scale-up challenges despite CordenPharma's support, and commercial headwinds such as payer reluctance to cover costly new obesity treatments. But the statistical improbability of VK2735's tolerability profile, combined with the manufacturing validation and institutional positioning, suggests the smart money sees something the broader market is missing. My personal take on the maximum upside? If VK2735 secures oral GLP-1 leadership and achieves widespread commercial adoption, a strategic acquisition could command valuations approaching $750 per share within the decade -- though this remains a highly speculative scenario contingent on flawless execution. A lot has to happen between now and then to make this come to fruition. But the seed has been planted. VK2735 has a real shot at bending the curve on the obesity epidemic. Markets move in cycles. "Returning is the motion of the Tao," as Lao Tzu wrote -- when one extreme is reached, movement toward the opposite begins. Biotech will rise again. Viking offers investors a chance to front-run that rotation -- not by chasing speculative names, but by owning a promising asset with game-changing potential at what may prove to be generational lows. As biotech's cycle inevitably turns, those positioned early in assets like Viking may capture the steepest part of the revaluation curve. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor 's total average return is1,049% — a market-crushing outperformance compared to179%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025 George Budwell has positions in Pfizer and Viking Therapeutics and has the following options: long January 2026 $55 calls on Viking Therapeutics, long January 2026 $60 calls on Viking Therapeutics, and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends Amgen, Goldman Sachs Group, and Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.

Meet the U.S. climate resistance
Meet the U.S. climate resistance

CBC

time4 hours ago

  • CBC

Meet the U.S. climate resistance

Hello, Earthlings! This is our weekly newsletter on all things environmental, where we highlight trends and solutions that are moving us to a more sustainable world. Keep up with the latest news on our Climate and Environment page. Meet the U.S. climate resistance U.S. climate advocates have faced a dizzying number of environmental policy rollbacks and funding cuts in the almost six months since Donald Trump took office. Now, activists, academics and lobbyists across American society are gearing up to once again galvanize public opinion in favour of climate action, ahead of the U.S. midterm elections in 2026. The academic resistance Brandon Jones is the president of the American Geophysical Union (AGU) who worked as a federal scientist in the Environmental Protection Agency (EPA) for 12 years. Jones says he was initially overwhelmed by the "surreal" barrage of changes. But now, Jones says, his organization is finding ways to push back. "You get to a point where yes, you are going to have emotions about the decisions, but you also need to start thinking clearly about how to stand up against what you know is not right," he said. In April, the U.S. president dismissed hundreds of scientists working to compile the country's flagship report on global warming and its impacts. The National Climate Assessment, which is released every four years, informs everything from agricultural policy that impacts food security to disaster mitigation that saves lives. These dismissals prompted the AGU to create a special collection of journals that would house all the important climate research that was suddenly left homeless. Jones says it's important for U.S. scientists today to find new ways to keep climate science alive in the face of federal funding cuts and shifting political priorities. Equally, he says, it's important to continue to get climate data out to decision makers and the general public, and he says many researchers in his circle feel the same. "They are so impassioned about continuing their work and doing the right thing in the face of what they see as an infringement on science … that they're just ready to do it with no pay. It's about ethics and morality now and humanity." The street-level resistance Youth organizations are putting their energy into more visible forms of resistance, like street protests and direct action. One example is the Sunrise Movement. Executive Director Aru Shiney-Ajay says they are currently forming a "youth army to combat the climate crisis." Sunrise's strategy is to carry out social media campaigns and hold rallies to draw attention to Donald Trump's support of fossil fuel industries ahead of the midterms. "Environment is the issue where Trump is least trusted," she said. "I think because of that, there's a real role to make climate a more urgent political priority for everyday people, and [it] actually can result in big shifts in the electorate." Peaceful protesters, however, are becoming increasingly vulnerable to criminal punishment in the U.S. Since January, an expanding list of bills have been introduced aimed at banning political demonstrations, according to The International Center for Not-for-Profit Law, a civic freedoms watchdog based in the U.S. capital. Shiney-Ajay says she's thought a lot about the consequences of organizing protests, but she hopes taking to the streets can inspire others to take smaller actions, like voicing support for climate policy in their workplaces, schools or online. "The question of whether or not we will be able to get out of this political situation really relies on how many people we can inspire to take everyday acts of courage, over and over and over again." Resistance by lobbying Climate organizations are also working to lobby Republican politicians on policies that reduce greenhouse gas emissions from industry. Glen Brand, director of policy and advocacy at the non-profit Solar United Neighbours, says the best way to do that is to focus on the economic benefits of renewable energy, rather than try to bring climate change into the conversation. The U.S. has recently experienced a boom in solar and wind energy uptake, especially in Republican leaning states. Brand attributes this boom to the rising cost of fossil fuel energy sources as well as tax credits brought in under former President Joe Biden that incentivize renewable energy infrastructure. While the Trump administration plans to phase those tax credits out, Brand hopes to convince Republicans to fight for the future of solar in their constituencies. "I think it makes total common sense, considering the state of the Republican Party and climate protection, to focus on pocketbook issues," he said. Dominque Browning, co-founder of the advocacy group Moms Clean Air Force, says her organization plans to lobby in favour of The Endangerment Finding. That's a 2009 decision by the EPA that acknowledges the public health dangers of greenhouse gas emissions and its responsibility to protect Americans from climate change. The current head of the EPA says he will consider reversing the finding altogether. Browning says she thinks about her grandson's future when preparing to push back against a reversal of the finding, and that parents across the U.S. are engaging with lawmakers to pressure the government to uphold the principles of the Endangerment Finding. "We will continue to fight on all fronts. In fact, we find that our work actually helps give us hope and solace, because at least we're trying to do something." Check out our podcast and radio show. In one of our newest episodes: If Canada wants to be net-zero by 2050, more than a million small businesses will have to make the green transition. And while some intrepid business owners are already trying their best to navigate a more eco-friendly path, others say it's a big ask, especially when many are already struggling to balance the needs of price-wary shoppers with a thin bottom line. We'll dive into their journey, and learn more about the supports that could change the game. What On Earth drops new podcast episodes every Wednesday and Saturday. You can find them on your favourite podcast app or on demand at CBC Listen. The radio show airs Sundays at 11 a.m., 11:30 a.m. in Newfoundland and Labrador. Reader Feedback We got another response to our request for photos of your native plant gardens! Amanda Blain wrote: "I have naturalized over five acres into trees, wetlands and native flowers and grasses BUT this is what I call my 'Landscaped Area.' I chose this to show even on a small scale you can make an impact. Instead of planting non-native plants as most landscapers do, I decided to take it into my own hands. I am located in Chatham-Kent, [Ont.,] where tree cover and natural areas are less than five per cent of the total land area. Here I planted: black-eyed Susan (Rudbeckia hirta), smooth oxeye or false sunflower (Heliopsis helianthoides), wild bergamot (Monarda fistulosa), common evening primrose (Oenothera biennis), purple coneflower (Echinacea purpurea), lanceleaf coreopsis (Coreopsis lanceolate) amongst others. I truly believe there is no reason to plant non-native flowers since there are so many beautiful native options." We also heard back from Boston's Office of Green Infrastructure about Sara Scharf's comment about the impact of road salt on Boston's roadside bioswales. Rachel Luna, the office's interim director and principal engineer, responds: "For our roadside bioswales, we select plant species tolerant of higher salt conditions. The first flush of runoff usually has the highest concentration of salt, but as additional ice and snow melts, it flushes the salt through the soil. We use well draining bioretention soil that helps the salt flush through easier." Feel free to send more photos of your native plant gardens — when you send them in, please include your location and what plants are included in the photo so other readers know what works in their region. The Big Picture: What your summer will feel like in 2100 By 2100, with a medium emissions scenario (similar to the trajectory we're on), Montreal summers could feel like ones already experienced in Chicago, Columbus, Ohio, or Queens, N.Y. CBC News published a new interactive analysis in which you can pick your city and see what cities have a present-day climate similar to the one your city will experience at the end of the century. These kinds of comparisons, called spatial analogues by scientists, are a useful way to transform sometimes abstract projections into concrete examples. — Nael Shiab British singer Ed Sheeran can afford a private jet. But he recently explained in an online interview why he doesn't own one, and prefers to travel by train (hint: it has to do with his views on the environment), The Cool Down reports. Hotels have stringent hygiene protocols that require toiletries, even if they're unopened, to be thrown out at the end of a guest's stay, reports Reasons to be Cheerful. But a number of organizations now collect hotel soap, reprocessing it if necessary, and redistribute it to those in need, including Canada-based Soap for Hope. Artificial light is extending the growing season in cities. On average, it's more than 12 days earlier and 11 days later, according to a new study looking at 428 cities across the northern hemisphere, compared to surrounding rural locations. The extra time for trees and plants means they could potentially absorb more CO2, but the extended season means that they are also susceptible to frost damage and could disrupt pollinator patterns. Find out more in Nature Cities. The town of Adjuntas has Puerto Rico's first community-owned solar microgrid, putting an end to high electricity costs and regular blackouts. The Guardian takes us on a photo tour of the town. China is already the global leader in electric car production. could boost China's dominance even more. (Paywalled) Sask. company using flax waste to create sustainable cat litter The Regina Humane Society is partnering with Prairie Clean Energy (PCE) to introduce a locally made, environmentally friendly kitty litter made from flax straw. Prairie Clean Cat Litter is made entirely from flax straw, a waste product left over when flax is harvested. "It is completely biodegradable, completely natural, and it eliminates the cat pee smell," said Mark Cooper, CEO of PCE in Regina. "Your houses are going to smell cleaner, your cats are gonna be happier, you're gonna have less ammonia in your home, and it is all Saskatchewan-made flax." Cooper said the company was looking for innovative ways to recycle flax straw. "We really focus on stopping the burning of flax straw, creating new revenue streams for farmers processing that straw, and creating multiple product streams that we sell around the world, only one of which is cat litter, but it's an important one," he said. Its other products include flax fibre for making pulp and paper, biomass fuel pellets and animal bedding. Cooper said PCE has been working with the Humane Society for a year testing out the litter and received positive feedback. "Once they were satisfied that we had a good product on our hands," he said. "We started putting together a partnership that would make sense for them to help reduce their operational costs, and would connect the cats and cat people with a great litter option." Now when people adopt a cat from the humane society, they can also take some of the Prairie Clean Cat Litter home. It's not yet available in stores. "So we've really structured a partnership to benefit cats and the people that love their cats," Cooper said. Dr. Catherine Ball, director of veterinary care at the Regina Humane Society, said it used the litter for 40 cats. "We observed what happened with those cats, as well as with a similar group of cats that had clay litter, and we were able to find out that this product from PCE performed very well," she said. Traditional clay litters can get stuck onto the bottom of cats' paws. Ball said that happened less using the flax straw litter. According to the company's website, the flax absorbs liquids rather than clumps like clay litter. Cooper said the humane society adopts out 1,500 cats per year. "We know that those cats will be using our litter and that every single person who adopts a cat from the Humane Society will leave with a free bag," he said. "Our intention is to roll out this partnership to humane societies everywhere." — Darla Ponace

Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment

Globe and Mail

time12 hours ago

  • Globe and Mail

Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's, ' Mycosis Fungoides Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Mycosis Fungoides pipeline landscape. It covers the Mycosis Fungoides pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mycosis Fungoides pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Mycosis Fungoides Pipeline. Dive into DelveInsight's comprehensive report today! @ Mycosis Fungoides Pipeline Outlook Key Takeaways from the Mycosis Fungoides Pipeline Report In June 2025, M.D. Anderson Cancer Center announced a study of ultra-low-dose-total-skin electron beam therapy with brentuximab vedotin (ULD-TSEBT+BV) among patients with stage I-IV mycosis fungoides/Sezary syndrome. In June 2025, Soligenix conducted a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. All of the participant's lesions that are readily available for exposure to the visible light source will be treated and 3 to 5 index lesions in each patient will be prospectively identified and documented for modified Composite Assessment of Index Lesion Severity (mCAILS) evaluation. Participants will be followed every 4 weeks for a total of 12 weeks following their last light session. DelveInsight's Mycosis Fungoides Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Mycosis Fungoides treatment. The leading Mycosis Fungoides Companies such as Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Promising Mycosis Fungoides Pipeline Therapies such as Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Stay ahead with the most recent pipeline outlook for Mycosis Fungoides. Get insights into clinical trials, emerging therapies, and leading companies with Mycosis Fungoides @ Mycosis Fungoides Treatment Drugs Mycosis Fungoides Emerging Drugs Profile Hypericin: Soligenix HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. Currently, the drug is in Phase III stage of its development for the treatment of Mycosis Fungoides. IPH4102: Innate Pharma Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Lacutamab has been granted U.S. FDA Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome. Innate Pharma SA announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab. Currently, the drug is in Phase II stage of its development for the treatment of Mycosis Fungoides. The Mycosis Fungoides Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Mycosis Fungoides with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mycosis Fungoides Treatment. Mycosis Fungoides Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Mycosis Fungoides Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mycosis Fungoides market Explore groundbreaking therapies and clinical trials in the Mycosis Fungoides Pipeline. Access DelveInsight's detailed report now! @ New Mycosis Fungoides Drugs Mycosis Fungoides Companies Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Mycosis Fungoides Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Mycosis Fungoides Treatment. Learn about new drugs, Mycosis Fungoides Pipeline developments, and key companies with DelveInsight's expert analysis @ Mycosis Fungoides Market Drivers and Barriers Scope of the Mycosis Fungoides Pipeline Report Coverage- Global Mycosis Fungoides Companies- Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides Pipeline Therapies- Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Mycosis Fungoides Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Mycosis Fungoides Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Mycosis Fungoides Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mycosis Fungoides Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Mycosis Fungoides: Overview Pipeline Therapeutics Therapeutic Assessment Mycosis Fungoides– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Hypericin: Soligenix Drug profiles in the detailed report….. Mid Stage Products (Phase II) IPH4102: Innate Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Mycosis Fungoides Key Companies Mycosis Fungoides Key Products Mycosis Fungoides- Unmet Needs Mycosis Fungoides- Market Drivers and Barriers Mycosis Fungoides- Future Perspectives and Conclusion Mycosis Fungoides Analyst Views Mycosis Fungoides Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store